WS
NWBO

Wedbush Securities’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Wedbush Securities’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-127,200
Closed -$44K – 914
2016
Q4 		$44K Sell
127,200
-35,000
-22% -$17.6K 0.01% 784
2016
Q3 		$88K Buy
162,200
+10,200
+7% +$4.66K 0.01% 762
2016
Q2 		$88K Buy
152,000
+9,560
+7% +$10.2K 0.01% 704
2016
Q1 		$208K Buy
142,440
+15,440
+12% +$30.5K 0.04% 579
2015
Q4 		$406K Hold
127,000
– – 0.07% 311
2015
Q3 		$794K Buy
127,000
+17,500
+16% +$164K 0.16% 149
2015
Q2 		$1.09M Buy
109,500
+33,000
+43% +$289K 0.2% 113
2015
Q1 		$564K Buy
76,500
+66,000
+629% +$444K 0.1% 241
2014
Q4 		$56K Sell
10,500
-15,000
-59% -$76.8K 0.01% 671
2014
Q3 		$128K Buy
25,500
+7,000
+38% +$43K 0.02% 619
2014
Q2 		$124K Buy
+18,500
New +$118K 0.02% 595

Other funds holding NWBO

MBT
Montecito Bank & Trust Santa Barbara, California $668M AUM 24.84% 1-Year Est. Return
WPP
Whalerock Point Partners Providence, Rhode Island $587M AUM 29.61% 1-Year Est. Return
MPI
Mairs & Power Inc St Paul, Minnesota $10.9B AUM 27.5% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $22.7B AUM

Wedbush Securities's NWBO Position: Q1 2017 in Review

Wedbush Securities sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q1 2017, closing a stake of 127,200 shares — an estimated $44K sold.

Wedbush Securities first reported a position in NWBO in Q2 2014 and held it in 11 quarters. The position peaked at $1.09M in Q2 2015. 4 funds tracked by Wall St. Rank hold NWBO as of Q1 2017.

  • Wedbush Securities reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q1 2017 after selling out during the quarter.
  • Wedbush Securities sold 127,200 Northwest Biotherapeutics, Inc. Common stock shares in Q1 2017, an estimated $44K.
  • Wedbush Securities first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2014 and held it in 11 quarters.
  • Wedbush Securities's Northwest Biotherapeutics, Inc. Common stock position peaked at $1.09M in Q2 2015.
  • 4 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q1 2017.

Based on Wedbush Securities's 13F filing for Q1 2017, filed 5 May 2017.